From: 5-FU induced cardiotoxicity: case series and review of the literature
Author | Cancer Studied | 5-FU regimen used | Number of patients | Overall 5-FU induced cardiotoxicity incidence (N) | Signs and symptoms |
---|---|---|---|---|---|
Polk et al. | Breast cancer | Capecitabinea | 452 | 4.9% (22) | Chest pain, dyspnea |
Jensen et al. | Colorectal cancer | FOLFOX4b | 106 | 8.5% (9) | Angina |
Holubec et al. | Colorectal cancer | de Gramont regimenc FOLFIRId | 42 | 57% (24) | Elevated cardiac biomarkers |
Yilmaz et al. | GI cancer | de Gramontc | 27 | 7.4% (2) | Angina |
Turan et al. | Not specified | Not specified | 32 | 12.5% (4) | Angina, ECG changes |
Ng et al. | Colorectal cancer | XELOXe | 153 | 6.5% (10) | Angina, Heart failure, Sudden cardiac death |
Meydan et al. | GI, Breast, and Head and Neck cancers | de Gramont regimenc | 231 | 3.9% (9) | Acute coronary syndrome, heart failure, cardiac arrhythmia |